Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population

2020 ◽  
Vol 267 (4) ◽  
pp. 1197-1205 ◽  
Author(s):  
Weihe Zhang ◽  
Lei Cui ◽  
Yeqiong Zhang ◽  
Wei Wang ◽  
Renbin Wang ◽  
...  
Keyword(s):  
Neuromyelitis Optica ◽  
Chinese Population ◽  
Spectrum Disorder ◽  
Free Form ◽  
Neuromyelitis Optica Spectrum Disorder

scholarly journals Aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder with recurrent short partial transverse myelitis and favorable prognosis: Two new cases

2017 ◽  
Vol 23 (14) ◽  
pp. 1950-1954 ◽  
Author(s):  
Jinhua Zhang ◽  
Fang Liu ◽  
Yiqi Wang ◽  
Ying Yang ◽  
Yuehong Huang ◽  
...  
Keyword(s):  
Neuromyelitis Optica ◽  
Transverse Myelitis ◽  
Acute Attack ◽  
Spectrum Disorder ◽  
Aquaporin 4 ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Attack Phase ◽  
Long Term Prognosis

Understanding the characteristics of neuromyelitis optica spectrum disorder (NMOSD) with recurrent short partial transverse myelitis (SPTM), which is very rare, contributes to the differential diagnosis of multiple sclerosis (MS). We present two Chinese aquaporin-4 immunoglobulin G (AQP4-IgG)-seropositive NMOSD cases who had at least twice SPTM during 4 and 6 years of follow-up, respectively. Their SPTMs have been mild and responded well to corticosteroids just like in the case of MS. The findings highlight the need of searching for serum AQP4-IgG (cell-based assay strongly recommended) in patients with recurrent SPTM and suggest that those patients may have a mild acute attack phase and favorable long-term prognosis.

scholarly journals Two Cases of Pediatric AQP4-Antibody Positive Neuromyelitis Optica Spectrum Disorder Successfully Treated with Tocilizumab

2019 ◽  
Vol 50 (03) ◽  
pp. 193-196
Author(s):  
Markus Breu ◽  
Sarah Glatter ◽  
Romana Höftberger ◽  
Michael Freilinger ◽  
Karl Kircher ◽  
...  
Keyword(s):  
B Cell ◽  
Neuromyelitis Optica ◽  
Spectrum Disorder ◽  
Cell Depletion ◽  
B Cell Depletion ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Interleukin 6 Receptor ◽  
Anti Cd20 ◽  
Aqp4 Antibody

AbstractB cell depletion with the anti-CD20-antibody rituximab is widely considered treatment of choice for long-term immunotherapy in aquaporin-4 (AQP4)-antibody positive neuromyelitis optica spectrum disorder (NMOSD). However, up to 30% of patients suffer from relapses despite complete B cell depletion. In these cases, the IL6 (interleukin-6)-receptor blocking antibody tocilizumab has been suggested as an alternative. We report two female adolescents with AQP4-antibody positive NMOSD who relapsed under rituximab treatment and clinically stabilized after switching to monthly administrations of tocilizumab. Our data suggest that early escalation of therapy with tocilizumab may lead to stabilization of disease activity in pediatric NMOSD patients who relapse under B cell depletion.

Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia

2019 ◽  
Vol 36 ◽  
pp. 101413 ◽  
Author(s):  
Jelena Drulovic ◽  
Vanja Martinovic ◽  
Irena Dujmovic Basuroski ◽  
Sarlota Mesaros ◽  
Simone Mader ◽  
...  
Keyword(s):  
Neuromyelitis Optica ◽  
Spectrum Disorder ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Term Outcome ◽  
Long Term Outcome

scholarly journals Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder

2015 ◽  
Vol 72 (7) ◽  
pp. 756 ◽  
Author(s):  
Marius Ringelstein ◽  
Ilya Ayzenberg ◽  
Jens Harmel ◽  
Ann-Sophie Lauenstein ◽  
Eckart Lensch ◽  
...  
Keyword(s):  
Neuromyelitis Optica ◽  
Interleukin 6 ◽  
Spectrum Disorder ◽  
Term Therapy ◽  
Receptor Blockade ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Highly Active ◽  
Interleukin 6 Receptor ◽  
Long Term Therapy
Sign in / Sign up

Export Citation Format

Share Document